News Johnson & Johnson Wiener Boerse

Equities

JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 01:13:21 03/07/2024 pm IST			5-day change	1st Jan Change
135.9 ^EUR	-0.66%		-1.10%	-3.46%

02/07	J&J: promising results in multiple myeloma	CF
02/07	Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

J&J: promising results in multiple myeloma	02/07	CF
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	02/07	MT
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	02/07	CI
State AG Updates: June 6-13, 2024	02/07	AQ
Momentum Picks Q3 2024: 5 stocks for the summer	01/07
CHMP adopts positive opinion for BALVERSA for the treatment of adult patients	01/07	AQ
Johnson & Johnson - Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class	01/07	AQ
New semester, new state of mind	01/07
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	29/06	PU
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	28/06	MT
J&J Unit's Rybrevant Combo Gets EU Approval	28/06	MT
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	28/06	PR
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	28/06	CI
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	28/06	PU
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	28/06	MT
Dealmakers optimistic on global M&A prospects despite sluggish growth	28/06	RE
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	28/06	BU
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	27/06	AQ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06	RE
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST